Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31434923 | 1.00 | ALDH1A1 (0.51) | ALDH1A1KDM4EMAPTHPGDLMNA | |
| SCHEMBL25215422 | 0.84 | ATM (0.59) | ALDH1A1KDM4EMAPTHPGDLMNA | |
| SCHEMBL30474724 | 0.83 | MAPT (0.48) | ALDH1A1KDM4EMAPTHPGDLMNA | |
| SCHEMBL30474733 | 0.83 | MAPT (0.51) | ALDH1A1KDM4EMAPTHPGDLMNA | |
| SCHEMBL25222434 | 0.83 | MAPT (0.51) | ALDH1A1KDM4EMAPTHPGDLMNA | |
| SCHEMBL25214594 | 0.83 | MAPT (0.48) | ALDH1A1KDM4EMAPTHPGDLMNA | |
| SCHEMBL30474781 | 0.81 | ATM (0.44) | ALDH1A1KDM4EMAPTHPGDLMNA | |
| SCHEMBL25242999 | 0.81 | ATM (0.44) | ALDH1A1KDM4EMAPTHPGDLMNA | |
| SCHEMBL25215319 | 0.80 | CA1 (0.47) | ALDH1A1KDM4EMAPTHPGDLMNA | |
| SCHEMBL23932348 | 0.80 | ALDH1A1 (0.43) | ALDH1A1KDM4EMAPTHPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043607-B2 | HDAC inhibitors and therapeutic use thereof | TANGO THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043607-B2 | HDAC inhibitors and therapeutic use thereof | TANGO THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043607-B2 | HDAC inhibitors and therapeutic use thereof | TANGO THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| WO-2023102162-A1 | TGONOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | TANGO THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| US-20230174501-A1 | NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | TANGO THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
| US-20230174501-A1 | NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | TANGO THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
| US-20230174501-A1 | NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | TANGO THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174501-A1 | NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | HDAC1, HDAC7, HDAC5 | ALDH1A1 495/4885KDM4E 308/4885MAPT 2684/4885 |
| US-12043607-B2 | HDAC inhibitors and therapeutic use thereof | HDAC1, HDAC7, HDAC5 | ALDH1A1 477/4885KDM4E 301/4885MAPT 2829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.